Ascentage Pharma Group International
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dajun Yang
- Full Time Employees
- 567
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Suzhou Industrial Park Suzhou People's Republic of China 215000
- IPO Date
- Jan 24, 2025
- CIK
- 0002023311
- Website
- ascentage.cn
- Similar Companies
- Business
- Ascentage Pharma Group International (AAPG; 6855.HK), founded in 2009 and headquartered in Suzhou, China, is a clinical-stage global biopharmaceutical company that discovers, develops, and commercializes novel small-molecule therapies targeting apoptosis pathways for cancers, chronic hepatitis B virus, and age-related diseases; it operates primarily in China with clinical trials across the United States, Europe, Australia, and Asia, and maintains offices in Beijing, Shanghai, Guangzhou, Taizhou, Sydney, and Rockville, Maryland. The company's core products include the approved BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351; brand name:耐立克), indicated for chronic myeloid leukemia in chronic phase resistant or intolerant to prior TKIs and newly approved for adult Ph+ acute lymphoblastic leukemia patients; the approved Bcl-2 selective inhibitor lisaftoclax (APG-2575; brand name:利生妥), for chronic lymphocytic leukemia and small lymphocytic lymphoma; alrizomadlin (APG-115), an oral MDM2-p53 inhibitor for solid tumors and hematological malignancies; pelcitoclax (APG-1252), a dual Bcl-2/Bcl-xL inhibitor for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma; APG-1387, an IAP inhibitor for advanced solid tumors and HBV; APG-2449, an oral FAK/ROS1/ALK inhibitor; APG-5918, an EED inhibitor; and other pipeline candidates addressing hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma. Ascentage Pharma focuses on oncology and hematology segments, serving patients with unmet needs through its innovative pipeline of nine registrational Phase III trials, including FDA- and EMA-cleared studies like GLORA-4 for lisaftoclax plus azacitidine in first-line higher-risk myelodysplastic syndrome. Recent developments include its Nasdaq listing (AAPG) on January 24, 2025, raising $126 million in its U.S. IPO; a July 2025 top-up placement generating $190.1 million in net proceeds; 93% year-over-year olverembatinib sales growth to $30.3 million in H1 2025 with expanded access via 782 pharmacies and hospitals; Takeda equity investment closure of $75 million in June 2024 and a December 2024 option agreement for olverembatinib licensing with $100 million upfront; ongoing global partnerships with AstraZeneca, Merck, Pfizer, Innovent Biologics, and institutions like MD Anderson Cancer Center and Mayo Clinic; and third breakthrough therapy designation for olverembatinib in frontline Ph+ acute lymphoblastic leukemia.
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of “Buy” from Analysts
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update
Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
Analyzing CSL (OTCMKTS:CSLLY) and Ascentage Pharma Group International (NASDAQ:AAPG)
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026